文献速递免疫规划传染病防控与疫情报告

韩国18岁及以上人群接种NVX-CoV2373新冠肺炎疫苗的安全性监测

Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over.
PubMed 文献 · Vaccine · 2023-06-27

在韩国,2022年2月14日起对18岁及以上人群接种NVX-CoV2373(诺瓦瓦克斯)新冠肺炎疫苗。本研究基于国家疫苗安全数据(新冠肺炎疫苗接种管理系统和短信调查)分析不良事件报告频率与严重程度,发现未识别出重大安全问题,且65岁及以上人群不良事件少于18-64岁人群。

要点

  • 基于CVMS,每10万剂不良事件报告率:加强针84.0,第1剂254.6,第2剂272.9。
  • 基于CVMS,每10万剂报告率:65岁及以上83.4,18-64岁168.1。
  • 基于TMS,65岁及以上人群局部和全身不良事件低于18-64岁人群(p < 0.001)。

核心结论

  • 总体未识别出重大安全问题,且韩国65岁及以上人群接种NVX-CoV2373新冠肺炎疫苗后不良事件较少。

研究设计与样本

  • 基于韩国国家疫苗安全数据(新冠肺炎疫苗接种管理系统和短信调查)分析不良事件。
  • 疫苗接种对象为2022年2月14日起18岁及以上人群。

主要发现

  • CVMS显示每10万剂不良事件报告率:加强针84.0,第1剂254.6,第2剂272.9。
  • CVMS显示每10万剂报告率:65岁及以上83.4,18-64岁168.1。
  • TMS显示65岁及以上人群局部和全身不良事件低于18-64岁人群(p < 0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the Republic of Korea (Korea), the NVX-CoV2373 (Novavax) coronavirus disease 2019 (COVID-19) vaccination was administered to 18-year-olds and over from February 14, 2022. This study sought to assess the frequency and severity of reported adverse events following the Novavax COVID-19 vaccination in Korea. METHODS: Adverse events based on two national vaccine safety data were analyzed; the COVID-19 vaccination management system (CVMS) and the text-message survey (TMS). RESULTS: CVMS identified that the reporting rate of adverse events per 100,000 doses were lower after booster doses (84.0) than after dose 1 (254.6) or dose 2 (272.9); and in 65-year-olds and over (83.4) than in 18- to 64-year-olds (168.1). The TMS found that local and systemic adverse events were lower in 65-year-olds and over than in 18- to 64-year-olds (p < 0.001). CONCLUSIONS: Overall, we identified no major safety issues and fewer adverse events following the Novavax COVID-19 vaccination among 65-year-olds and over in Korea.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kim S, Ko M, Heo Y, et al. Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over. Vaccine. 2023. PMID: 37422379. doi:10.1016/j.vaccine.2023.06.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。